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Summary
Objectives: Brucellosis, whether in an endemic region or not, remains a diagnostic puzzle due to
occasional misleading unusual presentations and non-specific symptoms. Presented herein is our
14-year experience with acute brucellosis at Sparta General Hospital, Lakonia, Greece.
Methods: A case series of 144 patients admitted to the internal medicine, pediatrics, and urology
departments, through evaluation of history, occupational data, serological tests, cultures of
blood and other body fluids, and imaging studies. Patients were treated with a 21-day course of
intramuscular streptomycin and a prolonged two-month course of doxycycline with a six-month
follow-up.
Results: Infected patients had a relevant occupational history in fewer than 20% of cases. Clinical
manifestations included non-specific symptoms (fever, malaise, sweats, arthralgias, lower back
pain, headache), findings such as splenomegaly (51%), osteoarticular involvement (42%), cervical
lymphadenitis (31%), hepatomegaly (25%), genitourinary involvement (13% of men), cholecystitis
(2%), breast abscess (0.7%), and acute abdomen (0.7%). Ninety-five percent of the patients had a
serological titer1/160 with culture-proven brucellosis. Overall, 82% of blood cultures and 100%
of other body fluid cultures (synovial, bile) were positive. Ninety-seven percent of the patients
were cured. Relapse in the follow-up period was observed in four patients who had not complied
with treatment.
Conclusions: Brucellosis is an infection with multiple presentations, and whether in an endemic
region or not, a thorough history of exposure and clinical suspicion are required since thresholds in
serological evaluation may lead to misdiagnosis and withholding of adequate treatment.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Corresponding author. Tel.: +302733022001; fax: +302733029010.
E-mail address: ermanitari@hotmail.com (P. Andriopoulos).
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Table 1 Demographic and occupational data of 144 patients
with acute brucellosis
Feature No. of patients Percent
Gender
Male 93 65
Female 51 35
Children 19 13
Male 11 58
Female 8 42
Adults 125 87
Male 82 66
Female 43 34
Rural residence 82 57
Urban residence 62 43
Farmer 72 58
Office worker 16 13
Abattoir worker 3 2
Animal breeder 25 20
Housewife 9 21Introduction
Since its first description by Marstan in 1860,1 brucellosis
remains a debilitating illness of global distribution. The
Mediterranean basin and Greece in particular, are two of
the most endemic regions worldwide.2 For its size, Lakonia,
a small and mostly rural county of approximately 80 000
inhabitants, has an unusually high annual incidence of new
infections due to poor preventive measures and inadequate
public health policies. Since brucellosis presents with a
wide clinical spectrum3—5 and often with vague and non-
specific symptoms, the diagnostic work-up is always a chal-
lenge for the clinician. In this paper, we report our 14-year
experience with acute brucellosis at Sparta General Hospi-
tal, Lakonia, Greece, focusing on the clinical findings,
occupational history, laboratory evaluation, and treatment
of hospitalized patients.
Materials and methods
Sparta General Hospital is a public institution that provides
secondary care to people living in the county of Lakonia. The
population, comprising both Greeks and immigrants (about
4% from eastern European countries), lives in rural areas (of
less than 500 inhabitants) with regular exposure to animals,
or they consume local animal products. It is not uncommon
for residents to come into contact with Brucella-infected
sheep and goats or to acquire a food-borne infection.
One hundred and forty-four patients discharged with a
diagnosis of acute brucellosis from 1990 to 2003 were iden-
tified via a review of the hospital medical records. Extracted
information included demographic data, clinical presenta-
tion, serologic and blood culture results, treatment, and
clinical course.
Serologic evaluation was performed using Brucella agglu-
tination tests (the Rose Bengal slide agglutination test and
the Wright standard tube agglutination (STA) test). All sera
were routinely tested both in low and high dilutions (from 1/
40 to 1/3200) in order to avoid negative results due to the
prozone phenomenon. A titer of 1/160 or higher was deemed
strongly suggestive of acute infection, and titers of 1/40 to 1/
80 were considered suspicious in view of the endemicity in
our region (no single titer was dismissed without being
analyzed in light of historical, epidemiologic, and clinical
findings). Since all patients presented with fever, blood
cultures were obtained independently of STA titers. Prior
to 1993, blood and other body fluids were cultured in classic
biphasic Castaneda flasks. Subsequently, the microbiology
department switched to an automated blood culture system
(Vital Aer-BioMerieux, Marcy L’Etoile, France) that shortened
the time needed to detect Gram-negative cocco-bacilli
expressing urease activity and requiring CO2. Isolates were
identified as Brucella species with conventional biochemical
tests and agglutination tests. In view of our diagnostic limita-
tions, further identification of Brucella strains was not per-
formed routinely. If the clinical localization of infection was
unusual, the samples were sent for further analysis and
identification. Patients aged 14 years and older were treated
with intramuscular streptomycin for 21 days plus a two-
month course of 100 mg of doxycycline twice daily. Patients
under 14 years of age were treated with oral rifampin plus co-trimoxazole for a period of six weeks. Susceptibility to
streptomycin, doxycycline, co-trimoxazole, rifampin, cipro-
floxacin, and tetracycline was assessed using a Kirby—Bauer
agar diffusion test. Isolates remained fully susceptible during
the study period.
The mean follow-up period was six months; given the rural
character and lack of adequate primary care network in our
region, longer-term follow-up for most patients was not
feasible. A relapse was defined as improvement after initia-
tion of treatment and reappearance of the symptomswithin a
month after the end of the prescribed regimen. Cure was
defined as no recurrence of symptoms and signs during the
six-month follow-up.
Results
Demographic and occupational data
Included in the analysis were 144 patients. One hundred
and nineteen (83%) patients were admitted to the internal
medicine department, 13 to pediatrics, and 12 to urology.
Overall, this represented 2—10 per 1000 patients discharged
from these three departments during the study years. The
annual patient distribution is shown in Figure 1, and Table 1
summarizes the demographic data of study patients. An
occupational history relevant for Brucella exposure was
present in only 24% of the 125 adults (<20% for the entire
study cohort), while the remaining subjects had probably
consumed contaminated animal products.
Clinical manifestations
Fever, malaise, sweating, lower back pain, and arthralgias
were the most common presenting symptoms, each with a
duration of less than seven days. All patients were febrile
but none presented with sepsis. The severity of symptoms
varied from mild illness to severe painful localized disease.
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Table 3 Features of Brucella infection, according to organ
system
Figure 2 Standard tube agglutination (STA) test results on
presentation.
Figure 1 Annual distribution of hospitalized patients with
brucellosis. The 1999 peak is concordant with the recorded
increase of infection rates in our region.5Table 2 summarizes symptoms and clinical findings. Localized
single organ involvement accounted for 64% of cases, while
32% of subjects presented with multiple osteoarticular,
genitourinary, gastrointestinal, or hematopoietic localiza-
tion (Table 3).
Diagnosis
Patients were initially evaluated with serologic tests and
blood cultures. Of the 144 patients, 137 (95%) had an initial
STA titer >1/160 (Figure 2) and a positive Rose Bengal test.
Most of these patients had a subsequent increase in titer,
although 11 (8.5% of 129, since 15 patients had a titer on
presentation 1/3200) did not have such an increase. All theseTable 2 Clinical manifestations in 144 patients with acute
brucellosis
No. of patients Percent
Symptoms
Fever 144 100
Malaise 140 97
Sweats 138 96
Arthralgias 125 87
Lower back pain 104 72
Headache 95 66
Findings
Splenomegaly 74 51
Osteoarticular involvementa 60 42
Cervical lymphadenitis 45 31
Hepatomegaly 36 25
Genitourinary involvementb 12 13
Cholecystitis c 3 2
Breast abscess 1 0.7
Acute abdomen 1 0.7
a Details on osteoarticular and genitourinary involvement are
displayed in Table 3.
b Genitourinary involvement accounts for 12 of 93 male
patients.
c Cholecystitis was diagnosed in patients with fever, abdominal
pain with positive Murphy’s sign, ultrasound evidence of gall-
bladder involvement, and serologic and culture results confirming
Brucella infection. Cholecystitis was both calculous (one patient)
and acalculous (two patients).patients were considered Brucella-infected and treatment
was begun immediately.
Overall, 82% of blood cultures were positive. Negative
results were associated with serologic titers higher than 1/
1600 and localized infection affecting only a single system
(e.g., monoarthritis of shoulder, spondylitis, etc.). All cul-
tures of body fluids, such as synovial fluid and bile, and
abscess aspirates grew Brucella spp. Such cultures wereNo. of patients Percent
Osteoarticular involvement 60 42
Spondylitis 41 28
Spondylitis with
neurologic impairmenta
3 2
Hip 12 8
Sacroiliitis 9 6
Knee 8 6
Shoulder 3 2
Wrist 3 2
Ankle 1 0.7
Sternoclavicular 1 0.7
Hematologic complications 28 19
Normocytic anemia 24 17
Neutropenia 6 4
Thrombocytopenia 2 1
Genitourinary involvementb 12 13
Epididymoorchitis 11 12
Prostatitis 1 0.7
Gastrointestinal involvement 15 10
Hepatitis 9 6
Cholecystitis 3 2
Diarrhea 2 1
Peritonitis 1 0.7
a Neurological impairment consisted of pain, paresthesias, and
diminished muscle strength to the affected neural root; L4—L5
was the localization in each case (one bilateral, two unilateral).
b Genitourinary involvement accounts for 12 of 93 male
patients.
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Figure 3 Magnetic resonance imaging (MRI) of a patient
with Brucella spondylitis and epidural abscess formation. The
patient was medically treated with a successful outcome,
with full neurological recovery, and without requiring surgical
decompression.obtained in conjunction with blood cultures and thus their
diagnostic utility was complementary. Diagnosis was via
serology alone for only 18% of cases.
In patients with antibody titers <1/160, appropriate
clinical suspicion and further evaluation led to a correct
diagnosis in seven (4.8%) patients, typically via positive
blood cultures.
Treatment and outcome
Patients over 14 years of age were treated with 1 g of
intramuscular streptomycin (adjusted for age in patients
over 70 years) for 21 days and a two-month course of
oral doxycycline 100 mg twice daily. Subjects under 14 years
of age were treated with oral rifampin and co-trimoxazole
according to body weight for six weeks. Surgical intervention
was required only in the patient with acute abdomen.6
Patients with spondylitis and neurologic impairment
(Figure 3) were treated medically and all made a
full recovery. At the six-month follow-up, 140 patients were
cured and a relapse was diagnosed in only four (3%). Relapse
was identified to have occurred as a result of non-adherence
to treatment because of photosensitivity in one subject and
early self-termination of treatment in three. For these
relapsed patients, clinical re-presentation was generally
milder and all were retreated with the same initial drug
regimen and evaluated again after six more months. One waslost to follow-up and the remaining three were then free of
signs and symptoms.
Discussion
Brucellosis is a zoonosis transmitted to humans from infe-
cted animals; Brucella melitensis is the most common and
virulent cause of the disease worldwide.4 Brucellae, small
aerobic Gram-negative bacilli, are killed by boiling or pas-
teurization of milk and milk products; they may survive up
to 8 weeks in unpasteurized white soft cheese and are not
killed by freezing.1,6 Infection occurs either through direct
inoculation or through consumption of contaminated food.
The majority of cases (84%) in our series involved food-borne
transmission and this may explain the male predilection seen
since it is common for men to consume local animal products
in village taverns. The highest number of cases reported in
1999 corresponds to a rise in the recorded infection rates
in the broader area of Peloponnisos, in which Lakonia is
located.7 The dramatic increase in brucellosis from 1997
to 2000 probably represents the insufficiency of veterinary
control and inadequate education of farmers. Since then,
public health measures designed to control disease trans-
mission from infected to healthy animals have resulted in
a minor drop in recorded cases.
The clinical presentation of brucellosis is often non-
specific with predominating symptoms like fever, malaise,
sweats, and headache. Dissemination via the bloodstream
can result in involvement of almost any organ.3 For the
experienced physician, localized disease is often easy to
recognize, but attributing more subtle findings to brucel-
losis requires epidemiologic knowledge and clinical suspi-
cion. In our series, the diagnostic procedure often required
culture of body fluids in order to establish the diagnosis. In
endemic areas serologic testing is considered to be diag-
nostic when titers of 1/320 to 1/640 are present,8 while
titers of 1/160 are considered suspicious. The sensitivity
and specificity of a serologic test are generally very
high.8 However, 18 of our patients had an initial titer of
1/160 and 20 a highest titer of 1/160. Since all of these
patients had culture-proven brucellosis, we emphasize that
a threshold cannot be defined and all titers, whether in an
endemic region or not, must be viewed as suspicious.
Therefore, when low antibody titers are encountered, cul-
tures of body fluids are mandatory in order to establish a
diagnosis. The rate of positive blood cultures in brucellosis
ranges from 15% to 80%.1 Acute brucellosis usually has a
higher frequency of culture positivity, while negative
results are more typically seen with the chronic form of
the disease or with localization of infection in a single
organ. The use of automated blood culture systems has
shortened the time needed for detection. In our study,
acute brucellosis (duration of symptoms <7 days) was asso-
ciated with a positive blood culture rate of 82%, and 100% of
cultured body fluids or abscess aspirates grew Brucella
organisms. These results are similar to those previously
reported in the literature.1,3,6,9
Osteoarticular involvement, especially spondylitis10 is
the most common form of localized brucellosis.1,11 The
infection may also affect prosthetic joints12 or become
clinically significant after a latent period.13 When disease
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positive and serologic and culture tests of the synovial fluid
may establish the diagnosis. Blood leukocyte counts usually
indicate bacterial inflammation.14 Genital infection is also
frequently seen and usually presents as epididymoorchitis or
occasionally as prostatitis, and most cases have multiorgan
involvement.15,16 Development of necrotizing orchitis may
require surgical treatment.15 Brucellosis can affect virtually
any tissue or organ, and various literature reports describe
Brucella infection of the respiratory system,17 the skin,18
and the gastrointestinal tract,19,20 and involving children.21
The clinician should conduct a thorough history looking for
animal or food-borne exposures when attempting to explain
non-specific symptoms suggesting brucellosis, but he/she
must bear in mind that many patients may not recall a
relevant epidemiologic exposure.
Brucella infection commonly causes mild hematologic
abnormalities2 such as anemia and leukopenia. Thrombocy-
topenia is far less common (<2% of cases) but there are
reports of thrombocytopenic purpura associated with bru-
cellosis,22 with high mortality due to hemorrhage into the
central nervous system.
For brucellosis the World Health Organization (WHO)
recommends six weeks of combination treatment with oral
doxycycline plus rifampin, or six weeks of doxycycline plus
21 days of streptomycin.23 Many studies have evaluated the
use of fluoroquinolones24 or macrolides25 without demon-
strating any in vivo superiority of these newer antibiotics. In
vitro susceptibility to all of these agents remains very high.
Monotherapy of brucellosis is associated with unacceptably
high rates of clinical relapses and is not recommended.26
Drug treatment for all of our adult patients, independent of
the site of infection, included streptomycin plus a prolonged
two-month course of doxycycline. This regimen was chosen
because of the rural character of our region, which made
proper monitoring of liver function tests (given the prolonged
course of rifampin) impossible, and also because of better
compliance with a simpler, single drug oral regimen. All 144
patients with acute infection responded favorably to treat-
ment without long-term complications.
Several limitations are present in our study. First, our
laboratory could not identify the isolated Brucella strains
because of diagnostic constraints. Newer diagnostic techni-
ques such as IgG and IgM antibodies and PCR for Brucella were
not employed because these tests are not available at our
institution. Imaging studies (e.g., magnetic resonance ima-
ging of the spine) were not routinely used. Most importantly,
our series represents only a fraction of brucellosis cases in our
county over the 14 study years. Private practitioners rarely
record such infections and we could not accurately estimate
their true incidence.
In conclusion, we emphasize that clinicians should never
forget brucellosis in the differential diagnosis of febrile
illness, especially in geographic areas where the disease
in endemic. The potential for unusual clinical presentation
and the low titers of serologic reactivity serve to remind
us that brucellosis remains always a diagnostic challenge
requiring clinical suspicion and thorough evaluation.
Furthermore, control and eradication of brucellosis depends
on the education of farmers, veterinarians, and the general
public and requires close epidemiologic surveillance of ani-
mal and human cases.Acknowledgments
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